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ABSTRACT 
Nasal polyps 
A clinical study of endoscopic score systems and epidemiology 
Leif Johansson, MD 
Department of Oto-Rhino-Laryngology, Central Hospital, Skövde, and Sahlgrenska 
Academy, University of Göteborg, Göteborg, Sweden 
Introduction: Nasal polyps are a common disease, the etiology and pathogenesis of which 
are still unclear. For diagnosis, a nasal endoscope is essential, while for follow-up treatment, a 
reliable score system is necessary. The existing score systems consist of few score steps and 
measure only large changes in polyp size. The question is whether a score system with a 
continuous scale will provide more reproducible, and sensitive results. The epidemiology of 
nasal polyps in the general population is not known. The main aims of this work were; to 
develop a sensitive and reliable method for assessing the size and extension of nasal polyps, 
and to determine the prevalence of nasal polyps in a general population. 
Methods: Different score systems, three newly developed and two established, were 
compared with regard to their ability to assess polyp size and detect changes during medical 
treatment. A total of 150 adult patients with nasal polyps were investigated in these studies. 
The new score systems used were: lateral imaging (LI), assessment of polyp obstruction, and 
nasal airway patency. The established score systems were ad modum Lildholdt et al. and ad 
modum Lund and Mackay. The score systems were compared with the patients' subjective 
symptoms. A nasal endoscope was used to get a good view of polyps in the entire nasal 
cavity. One investigator examined the patients twice, whereafter three otorhinolaryngologists 
examined 30 patients independently of each other, using the same technique and performing 
the investigations under the same conditions. Thereafter, the different methods of polyp 
staging were compared. The sensitivity of LI in comparison with the Lildholdt et al. score 
system was tested by measuring early (i.e., within 14 days), and small, changes in polyp size 
during treatment with a topical corticosteroid. In the epidemiological study, 1,900 adult 
subjects were randomly drawn from a small town register. Of these, 1,387 were examined 
with a nasal endoscope, tested for smell impairment, and questioned with regard to relevant 
medical conditions. Health-related quality of life (HRQL) was investigated among individuals 
diagnosed with nasal polyps and compared with that of individuals without nasal polyps and 
patients with symptomatic nasal polyps. 
Results: The reproducibility of all five score systems was good and the reliability between 
different investigators was significantly better for score systems LI, Lildholdt et al., and 
assessment of polyp obstruction than for the other two. The LI was significantly more 
sensitive and better able than the Lildholdt et al. score system to detect early changes in polyp 
size. The symptom score showed significant improvement after 3 days. The prevalence of 
nasal polyps in adults was 2.7%, and was more frequent among men and asthmatics, as well 
as with increasing age. The individuals with nasal polyps experienced the same frequency of 
asthma and reduced sense of smell as patients, and had impaired HRQL. 
Conclusion: Lateral imaging, evaluated by nasal endoscopy, has been shown to have good 
reproducibility and to be a reliable method for detecting early changes in polyp size. The 
prevalence of nasal polyps was 2.7% in the general adult population studied. Nasal polyps 
lead to reduced HRQL. Nasal polyps are a manifestation of a mucosal disease including both 
the upper and the lower airways. 
Key words: nasal polyps, score system, endoscope, epidemiology, airways, HRQL. 
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ABBREVIATIONS 
ANOVA analysis of variance 
CI confidence interval 
CT computerized tomography 
ENT ear, nose, and throat 
HRQL health-related quality of life 
IgE immunoglobulin E 
LI lateral imaging 
MRT magnetic resonance tomography 
n number 
OR odds ratio 
PNIF peak nasal inspiratory flow 
QoL quality of life 
SEM standard error of the mean 
SF-36 short form 36 health survey questionnaire 
SOIT Scandinavian Odor Identification Test 
VAS visual analog scale 
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DEFINITIONS 
Nasal polyp - pale glassy protuberance of the nasal mucosa 
Nasal polyposis - condition which comes with nasal polyps, and which requires medical or 
surgical intervention 
Peak nasal inspiratory flow - maximal voluntary flow of air through the nose during forced 
nasal inspiration 
Turbinate - mucosa-lined bony pouches of the lateral wall in the nasal cavity 
Visual analog scale - a continuous scale for measuring symptoms 
Prevalence - frequency of a condition in a population 
Middle meatus - area above the inferior turbinate and lateral to the middle turbinate in the 
nasal cavity 
Odds ratio - quotient between two odds (= probabilities) 
Upper airways - airway from the nose to the larynx 
Lower airways - airway of the trachea, and lungs 
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INTRODUCTION 
Nasal polyposis is a common disease not known to shorten life expectancy. The main 
symptoms are nasal blockage and olfactory impairment; also, nasal secretion and sneezing 
frequently accompany the condition. Nasal polyposis is often associated with other diseases, 
such as asthma, aspirin intolerance, chronic rhinosinusitis, dental infections, cystic fibrosis, 
the Churg-Strauss syndrome, Kartageners syndrome, and Young's syndrome. The 
relationship to asthma is most frequently investigated. Among patients with non-allergic 
asthma, nasal polyps are found in 13% and in 5% of allergic asthma, and among patients with 
nasal polyps, asthma has been reported in 70% (1-7). The prevalence of nasal polyps has 
been estimated to be 1^4% by several groups (8-10). In a retrospective study of patient files 
from an allergy clinic, the prevalence was 4.2% (1). In a Russian questionnaire study, the 
prevalence was 1.3-5.6% (11) and in a Finnish population-based questionnaire study from 
1999, the prevalence was reported to be 4.3% (12). In addition, Larsen and Tos reported the 
incidence of nasal polyps to be 0.6% (13). 
The etiology of nasal polyps is not fully understood and no single cause has been found. 
Nasal polyposis is sometimes classified as an allergic disorder, but no association with 
immunoglobulin E (IgE)-mediated allergy has been found (14). Polyps are considered to be 
an inflammatory process, and various mediators are thought to be involved in the 
pathogenesis (15-16). 
The nasal airway lumen is divided into two separate cavities by the nasal septum. The airway 
lumen comprises three turbinates, the upper, the middle, and the lower turbinate. Nasal polyps 
are generally found in the middle meatus, but occasionally they can originate from the upper 
part of the nose (17-19). Polyps are usually pale glassy protuberances of the nasal mucosa, 
with few blood vessels and sensory nerves (20-21). Histologically, they are often difficult to 
distinguish from the mucosal epithelium. It is common that polyps are characterized by an 
edematous stroma, hyperplastic goblet cells and, eosinophils and mast cells in the stroma (22). 
Until the late 1970s, nasal polyps were exclusively treated by surgery. Since then, however, a 
large number of controlled studies have verified the positive effect of topical corticosteroids 
for nasal polyps (23-38). Also, the development of endoscopy has improved the surgical 
results (39-40). In spite of effective treatments, nasal polyps frequently recur, and up to now, 
8 
nasal polyposis is a chronic disease, which repeatedly causes patients to consult the medical 
profession (41^3). 
For correct diagnosis and staging of nasal polyps, endoscopy is essential (44—46), while in 
evaluation of efficacy of treatment of nasal polyps, score systems are often used for staging. 
Most of these consist of three or four steps, expressing the vertical extension of the polyps 
(26, 27, 47). Published data on validity, and assessment of the sensitivity, of these methods 
are lacking, but the score systems seem to have some credibility following repeated use (26-
28, 30, 31, 34). Radiology, including computerized tomography (CT) and magnetic resonance 
tomography (MRT), has been proposed to be an objective method for assessing pathology in 
the nasal sinus complex. It gives additional information on the extension of polyps and sinus 
involvement, but has the disadvantage that it cannot distinguish between mucosal congestion 
and polyps (48). Following the outcome of treatment, physiological techniques for 
investigating airflow and nasal geometry are also useful, e.g., peak nasal inspiratory flow 
(PNIF), rhinomanometry, and acoustic rhinometry (49-50). Patients' experience of treatment 
effects can be assessed with various symptom scores. Long-standing nasal polyposis has been 
shown to be associated with impaired sense of smell (51). 
PRESENT INVESTIGATIONS 
Aims 
In many respects, nasal polyposis is a still unexplored disease and it is not known for certain 
whether the incidence is increasing or decreasing. Therefore, it is of certain importance to 
study the epidemiology of nasal polyps. As nasal endoscopy is the gold standard for diagnosis 
and assessment of nasal polyps, staging is fundamental to polyp research. 
The main aims of this work were to -
1. develop a sensitive and reliable method for assessing the size and extension of nasal 
polyps 
2. determine the prevalence of nasal polyps in a general population 
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Endoscopic staging study (Papers I and II) 
A total of 150 adult patients with nasal polyps (hereafter referred to as 'patients'), 108 men 
and 42 women, aged 19-79 years, were investigated in these studies. 
Score systems 
Different score systems, three newly developed and two established, were compared with 
regard to their ability to assess polyp size and detect changes in polyp size during medical 
treatment. In all systems, nasal endoscopy was used to define the extension of the polyps and 
no local anesthesia or decongestion was used. With endoscopy, it was possible to get a good 
view of polyps in the entire nasal cavity, with the exception sometimes of the upper, posterior 
part of the nose. A pilot study was performed, in which all investigators used the same 
technique and performed the investigations under the same conditions. The score systems 
were compared with the patients' subjective symptoms scored on a visual analog scale (VAS), 
where 0 = no nasal blockage, and 100 = a completely blocked nose (52). 
The score systems used were -
1. Lateral imaging (LI). The nasal polyps were defined and their size was assessed 
in a vertical and a horizontal plane. The extension of the nasal polyps was drawn 
on a standard schematic picture of the lateral wall of each nasal cavity (Fig. 1) and 
expressed in per cent of the lateral wall of the nasal cavity. The drawing was done 
using a computer program, with automatic calculation of the polyp area (Fig. 2). 
2. Assessment of polyp obstruction. The proportion of the total nasal cavity volume 
occupied by polyps was assessed. In the assessment, 0 = "no polyps", while 100 = 
"nasal cavity completely filled with polyps". 
3. Nasal airway patency. The proportion of the patent airway lumen in relation to an 
imaginary maximal nasal airway lumen was assessed, disregarding the presence 
of polyps and nasal mucosal swelling. In the results, 0 = "no lumen for 
ventilation", while 100 = "airway lumen ventilation as wide as possible", i.e., 
limited only by the static anatomical structures of the nose. 
4. Score system ad modum Lildholdt et al. The degree of nasal polyps in relation to 
the inferior turbinate was classified in four steps (0-3), where 0 = "no polyps"; 1 
= "small polyps not reaching the upper edge of the inferior turbinate"; 2 = 
"medium-sized polyps reaching between the upper and the lower edges of the 
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inferior turbinate"; and 3 = "large polyps reaching below the lower edge of the 
inferior turbinate". 
5. Score system ad modum Lund and Mackay. The size of nasal polyps was 
estimated in three steps, where 0 = "no polyps"; 1 - 'polyps confined to the 
middle meatus"; and 2 = "polyps beyond the middle meatus". 
Figure 1. Schematic picture of the lateral wall of the nasal cavity 
Figure 2. Computer-aided calculation of polyp size (extension of polyps in black). 
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Method 
In the first part of the study, one investigator examined the same 22 patients twice, with 2-
hour intervals between examinations, to compare the different methods of polyp staging. At 
the second examination, the patients were covered with a sheet with only a hole for the nose 
in order to be blinded to the investigator (Fig. 3). 
In the second part of the study, three otorhinolaryngologists examined 30 patients 
independently of each other. Thereafter, the sensitivity of LI was compared with that of the 
Lildholdt et al. score system, a symptom score (VAS), and PNIF, by measuring early (i.e., 
within 14 days) and small changes in polyp size during treatment with a topical corticosteroid 
(budesonide). With all five score systems, polyp size was calculated as a mean of the left and 
right side of the nasal cavity. 
Figure 3. Draped patient during nasal endoscopy 
Results 
In repeated assessments with one investigator, significant positive correlations between the 
first and the second assessment were found with all five methods used to score nasal polyps. 
The highest correlations were obtained with LI, followed by assessment of polyp obstruction 
and Lildholdt et al. 's score system.When three physicians examined the same patient, good 
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agreement was found, as indicated by the absence of statistically significant differences 
between the investigators' way of scoring using LI, nasal airway patency, and the score 
system ad modum Lildholdt et al. However, analysis of variance (ANOVA) revealed a 
significant difference between the physicians using the score system assessment of polyp 
obstruction and that of Lund and Mackay. Patients' symptoms of nasal blockage were poorly 
correlated to the extension of the polyps. 
Based on previous experience, the sensitivity of LI was compared with that of Lildholdt et 
al. 's score system. Whereas LI was able to detect significant changes in polyp size after 14 
days, no changes in polyp size could be detected with the score system of Lildholdt et al. 
during the 2-week period. Patients experienced symptomatic improvement after 3 days, 
measured using a VAS. However, the PNIF score did not show any significant changes in 
nasal flow during 14 days. 
Epidemiological study (Papers III and IV) 
Method 
Based on the lowest estimated prevalence of nasal polyps, of 1%, altogether 1,900 individuals 
aged 20 years and older, stratified for age (using 10-year intervals) and gender, were 
randomly drawn from the Skövde population register. They were invited for a nasal 
examination including a smell test. The subjects' medical history was gathered in a 
standardized manner by means of a structured interview designed to pick up relevant medical 
conditions like nasal blockage and secretion, asthma, aspirin intolerance, and smell 
impairment. 
Nasal endoscopy was performed in all individuals to detect nasal pathology and extension 
(LI) of found polyps. The sense of smell was measured by a qualitative test, the Scandinavian 
Odor Identification Test (SOIT), and nasal airflow was measured by PNIF (49, 50, 53, 54). 
Individuals found with nasal polyps in the population-based study (hereafter referred to, 
simply, as 'individuals'), together with patients and matched controls from the population-
based study, later participated in a study of signs and symptoms from the nose and the lower 
airways, and health-related quality of life (HRQL). In this part of the study, the short form 36 
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health survey questionnaire (SF-36) was used. This generic questionnaire contains 36 
questions measuring general aspects of HRQL (55-57) (see Table 1). 
Table 1. Description of health concepts in the SF-36 questionnaire 
Measure Number of items Definition 
Physical function (PF) 10 Extent to which health interferes with a variety of 
specific physical activities, such as sports, carrying 
groceries, climbing stairs, walking 
Role physical (RP) 4 Extent to which health interferes with usual daily 
activities, such as work, housework, or school 
Bodily pain (BP) 2 Extent of bodily pain experienced in the past 4 
weeks 
General health (GH) 5 Overall rating of current health in general 
Vitality (VT) 4 Energy or tiredness 
Social function (SF) 2 Extent to which health interferes with normal 
social activities, such as visiting friends, during the 
past month 
Role emotional (RE) 3 Extent to which health interferes with usual daily 
social activities (e.g., accomplished less than 
would have liked to) 
Mental health (MH) 5 General mood or affect, including depression, 
anxiety, and physiological wellbeing, during the 
past month 
Health transition (HT) 1 Evaluation of general perception of health during 
the past year 
Physical component 
summery (PCS) 
Summery index of the physical scales 
Mental component 
summery (MCS) 
Summery index of the mental scales 
Results 
In total, 1,387 volunteers (73% of the sample) were investigated. The sample size was 
adequate, with a good fit to the total population and representative to the Swedish population 
(Table 2). The dropouts were from among the youngest (20-30 years of age) and the oldest 
subjects (>70 years). Reasons for subjects dropping out of the study varied; in the youngest 
group, most dropouts had relocated, while in the oldest group, the incidence of dropout was 
due to incapacity or death. 
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Table 2. Comparison of study population and inhabitants in Sweden 
Group/age (year) 20-29 30-39 40-49 50-59 60-69 70-79 80+ 
Skövde 
Inhabitants/ 
Strata (%) 18 19 17 18 12 10 6 
Women/ 
Strata (%) 48 48 50 50 52 56 63 
Sweden 
Inhabitants/ 
Strata (%) 16 19 17 18 12 10 7 
Women/ 
Strata (%) 49 49 49 49 51 56 65 
Nasal polyps were found in 38 subjects (26 men and twelve women), which represents an 
overall prevalence of 2.7% (95% confidence interval (CI) 1.9;3.5%) in adults. Polyps were 
more common in men than in women (male:female ratio 2.2:1, mean age 62 years), with an 
odds ratio (OR) of 2.70 (95% CI 1.33;5.50). 
The prevalence increased with age: up to 40 years, the prevalence was <1%, while from 60 
years on, the prevalence approached 5%. Polyps were more common in asthmatics, with an 
OR of 5.20 (95% CI 2.48; 10.89). Subjective symptoms of aspirin intolerance did not increase 
the OR for nasal polyps. 
The 38 individuals with nasal polyps were further compared with age- and gender-matched 
controls from the population and with 44 patients (IV). The size of the nasal polyps was 
significantly larger among the patients than among the individuals. Smell impairment was 
equal in the two groups. Individuals and patients had asthma in 30% of cases, which was 
significantly higher than for the controls (5%). Peak nasal inspiratory flow was reduced in 
individuals, but not to the same extent as among patients. Nasal blockage was more frequent 
among the patients than it was in the individuals, but there was no significant difference in 
blockage symptom between individuals and controls (Table 3). 
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Table 3. Data of the individuals with nasal polyps, patients, and controls. 
Variable Individuals Patients Controls Individuals 
vs. Patients 
Individuals vs. 
Controls 
Number 38 44 38 
Men (n) 26 33 26 
Mean age (yrs) 62 52 62 
Symptoms 
Blockage (n) 19 40 11 PO.OOl n.s. 
Secretion (n) 6 15 4 n.s. n.s. 
Sneezing (n) 8 12 6 n.s. n.s. 
Reduced sense of smell (n) 18 33 6 P<0.05 PO.OOl 
Asthma (n) 12 16 2 n.s. P<0.01 
Aspirin intolerance (n) 2 4 0 n.s. n.s. 
Examinations 
Polyp size (mean LI %) 11.2 32.2 0 [5.8-16.6] vs. 
[24.5-39.8] 
PNIF 
mean (1/min) 
153 108 163 [132-174] vs. 
[87-130] 
[132-174] vs. 
[142-184] 
SOIT outcome (mean) 11.8 11.3 13.4 [10.6-13.0] 
vs.[9.9-12.6] 
[10.6-13.0] vs. 
f12.5-14.31 
There was a statistically significant impaired quality of life (QoL) for the SF-36 domains PF, 
RP and PCS for individuals, and for the domains PF, GH, VT, and PCS for patients compared 
with the normal values for the general Swedish population (58) (Table 4). 
Table 4. Difference in mean-score compared to Swedish norm 
Domain PF RP BP GH VT SF RE MH PCS MCS 
Swedish norm 87,9 82,3 74,8 75,8 68,8 88,6 85,7 80,9 50 50 
Individuals 75,3 68,4 69,8 69,4 66,8 85,3 80,4 82,6 45,0 54,5 
Swedish norm 
- Individuals 
12,6 13,9 5 6,4 2 3,3 5,3 -1,7 5 -4,5 
p-value 
Swedish norm 
- Individuals 
0.0059 0.053 0.28 0.15 0.62 0.43 0.34 0.59 0.018 0.011 
Patients 80,3 77,2 70,9 61,6 59,4 89,2 80,3 79,3 46,4 52,4 
Swedish norm 
-patients 
7,6 5,1 3,9 14,2 9,4 -0,6 5,4 1,6 3,6 -2,4 
p-value 
Swedish norm 
-Patients 
0.016 0.37 0.36 0.0005 0.019 0.80 0.31 0.54 0.022 0.10 
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DISCUSSION 
Nasal polyps have been defined in different ways. Our definition is based on Lund's (21) and 
Clement's definition (20). This definition does not include the mucosal pathology often seen 
by radiological examinations of the nose and sinuses. Rather, we chose to define polyps 
within the nasal cavity, whose extension can be examined by endoscopy. The diagnosis nasal 
polyposis has been used entirely for patients with a clinically significant disease. 
In Paper I, a rigid endoscope with a 4 mm diameter and an optical angle of 0° was used, while 
in Papers II-IV, we used an endoscope of 2.7 mm diameter, and a 30° angle. However, both 
endoscopes have a fairly wide angle (Fig. 4). Our experience is that the 2.7 mm endoscope is 
easier to handle. The avoidance of nasal anesthesia and decongestants has both pros and cons. 
Without nasal decongestants, we could see nasal polyps in their natural condition and thus 
assess the patients' nasal symptoms and measure their nasal airflow. Decongestion increases 
the view into the nose, but may lead to reduced polyp size. Anesthesia has no influence on 
polyp size, but it could influence the patient's experience of nasal blockage and, possibly, the 
olfactory function. It is possible that in some cases, we could have benefited from anesthesia 
and decongestants, especially in the middle meatus, but mostly, there was no need for local 
anesthesia. Furthermore, avoidance of pretreatment considerably saves time. 
Figure 4. Comparison of the 2.7 mm, optic angle 30°, with the 4 mm, optical angle 0°, 
endoscope 
liiiiiiii 
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Endoscopic staging study (Papers I and II) 
The LI score system measures the polyp size in two directions, giving the vertical and the 
horizontal extension. The score systems with three or four score steps only measure the 
vertical extension. Furthermore, one of the steps in these scores, score = 0, does not grade any 
polyps at all. Recently, a new score system was developed, which consists of a schematic 
picture of the nasal cavity with five score steps in vertical extension (46). The use of mean 
values for nasal polyps on the left and right side was based on the common way to calculate 
polyp size using the score system ad modum Lildholdt et al., although this score system is 
stepwise and is an ordinal scale. A comparison of mean and median values in our results 
revealed only slight differences which did not influence the outcome. For endoscopic staging 
of nasal polyps, no existing score method has been validated previously. 
Epidemiological study (Papers III and IV) 
This is the first study that shows the prevalence of nasal polyps following endoscopy in a 
general population of adults. The Skövde population-based study is considered to be 
representative of the Swedish population. However, it cannot be excluded that the prevalence 
of nasal polyps in adults, as well as its distribution among gender and age, varies in different 
countries. The differences in age between individuals with polyps in the population study and 
our patients could be explained by the fact that the patient material was not randomized (IV). 
Questions were presented in a structured interview. Structured interviews permit elucidation 
of questions where needed and are therefore preferable to a questionnaire. It is, however, of 
outmost importance that the questions have high specificity. Questions about asthma have 
previously been validated by Torén et al. (59). In that study, the question, "Have you had 
asthma or shortness of breath during the last 12 months?" was compared with physician 
diagnoses, with a specificity of 92% and a sensitivity of 62% (59). The questions about nasal 
polyps have previously been used in an epidemiological study, but we added the words "as an 
adult" to prevent misdiagnosis of the adenoid vegetations in children (12). The question about 
aspirin intolerance has also been used in the same study (12). 
The question that remains, however, is; What is the clinical significance of small, sometimes 
unilateral, polyps occasionally found during a general population-based study? These polyps 
seem to represent the same kind of disease as seen in patients with manifested polyposis (IV). 
However, we cannot be sure whether these polyps represent an early stage, a beginning of the 
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polyp disease, or perhaps an end of it. This is a question for a follow-up study of individuals 
with nasal polyps, e.g., after 5 years. 
In the present study, health-related quality of life, measured with a general health 
questionnaire (SF-36), showed significant differences between individuals and patients, and 
Swedish normal values in three and four domains respectively. This is in contrast to a French 
study, which reported significant HRQL differences (SF-36) between patients with nasal 
polyps and healthy controls in all eight domains (57). That study had a different design, 
including untreated patients with nasal polyps, while patients in our study were under 
medication with topical corticosteroids. In the French study, there was an improvement in all 
domains of SF-36 after treatment with a topical corticosteroid (57). 
CONCLUSION 
The LI score system, with evaluation by nasal endoscopy, has been shown to be a reliable 
method with good reproducibility and sensitivity for detecting early, and small, changes in 
polyp size. It can therefore be recommended for scientific purposes; however, for ordinary 
clinical use, it is often sufficient to trust the patient's symptoms and perform endoscopy. 
In the present study, the prevalence of nasal polyps was 2.7% in a general population of 
adults; and nasal polyps were seen to be more frequent at middle age and above, in 
asthmatics, and among men. Nasal polyps lead to nasal blockage and often, to reduced sense 
of smell. Nasal polyps are a manifestation of a mucosal disease including both the upper and 
the lower airways. 
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STATISTICAL METHODS 
Paper I For comparing different score methods and repeated investigations by one 
doctor, Pearson's coefficient of correlation was used. For interindividual 
comparisons between three investigators, ANOVA was used. 
Paper II Power calculation was based on an 80% chance of detecting a difference of 1.4 
score steps by the Lildholdt et al. score scale. The differences between the two 
treatment groups were calculated by means of ANOVA. 
Paper III Based on the lowest estimated prevalence of 1%, on 95% CIs, and on an 
estimated dropout rate of 20%, 1,900 individuals were randomly selected from 
the Skövde community register. The OR was calculated. Multiple logistic 
regression analysis was used to select explanatory variables for nasal polyps. 
Paper IV The chi2 test and ANOVA were used for comparing the different groups. In 
comparing different groups in SF-36 student-test were used. 
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SAMMANFATTNING PÅ SVENSKA 
Näspolyper är en kronisk inflammatorisk sjukdom i nässlemhinnan och förenad med nästäppa 
samt luktnedsättning. De bakomliggande orsakerna är inte är fullständigt klarlagda. Koppling 
till astma, aspirinintolerans och cystisk fibrös är väldokumenterade, men något 
orsakssamband med allergi har inte kunnat fastställas. Kunskapen om förekomsten av 
näspolyper ökar eller minskar, samt om yttre faktorer kan bidra till uppkomsten, saknas. 
Sjukdomens epidemiologi är dåligt känd, men den kliniska erfarenheten visar att den är 
vanligast bland män och ovanlig hos barn. Ett syfte med denna undersökning har varit att 
studera hur vanliga (prevalensen) näspolyper är i den vuxna befolkningen. 
Näspolyper behandlas kirurgiskt och/eller med nasala kortisonpreparat. Trots förbättrad 
behandling återkommer ofta polyperna efter en tid. För att kunna diagnostisera och mäta 
effekten av behandling av polyper används Fiberendoskop i ökad omfattning, med vilket 
djupare partier i näsan kan studeras. Radiologiska och fysiologiska undersökningmetoder kan 
ge information om polypsjukdomens utbredning men kan ej visa polypernas storlek. 
Ett annat syfte med studien var att jämföra ett nytt graderingsystem (Lateral imaging) med 
existerande graderingssystem för näspolyper i avsikt att se vilket som är känsligast. 
Studien består av två delar, en metodologisk del och en epidemiologisk del. I den 
metodologiska delen undersöktes totalt 150 vuxna patienter med näspolyper och i den 
epidemiologiska 1387 slumpvis utvalda vuxna individer frän normalbefolkningen. Tre nya 
egna scoresystem och två etablerade jämfördes och reproducerbarheten vid upprepade 
mätningar och mellan olika bedömare undersöktes. Lateral imaging, en metod, där man 
projicerar polypernas utbredning i näsan på en skiss av näsan i en dator , som räknar ut 
polyputbredningen i p rocent, visade sig ha god reproducerbarhet. Jämfört med en av de 
etablerade scoremetoderna (ad modum Lildholdt et al) hade Lateral imaging en bättre 
känslighet, då denna metod kunde mäta tidig effekt av en medicinsk behandling med nasal 
kortisonspray. Prevalensen för näspolyper bestämdes till 2,7 % [95-% konfidensintervall: 1.9-
3.5 %],. Risken för att ha näspolyper var högre för män och astmatiker. Frekvensen av 
näspolyper ökade med stigande ålder. En livskvalitetsstudie visade att näspolyper leder till 
försämrad livskvalitet, både bland individer med polyper från populationsundersökningen och 
bland patienter med symtomgivande näspolyper. Näspolyper leder till nästäppthet och 
subjektivt försämrat luktsinne, men också till symtom från de nedre luftvägarna. 
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